pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
the cabinet
Drugs
8,127
products tracked
★ save view
↓
export CSV
search
phase
all
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
sort
catalysts
recent
name
therapeutic area
all
Oncology
1831
Infectious Disease
718
Cardiology
425
Pulmonology
396
Immunology
371
Ophthalmology
368
Dermatology
300
Women's Health
view
list
cards
Phase 1
LP-118
Anaplastic Large Cell Lymphoma (ALCL)
Newave Pharmaceutical Co Ltd
0
catalysts
Preclinical
LP-182
Myelofibrosis
Lympharma LLC
0
catalysts
Phase 2
LP-184
Central Nervous System (CNS) Cancer
Starlight Therapeutics Inc
0
catalysts
Phase 1
LP-284
B-Cell Non-Hodgkin Lymphoma
← prev
page 119 of 271
next →
131
Pain
89
Neurology
1
$LTRN
Lantern Pharma Inc.
0
catalysts
Phase 2
LP-310
tacrolimus
Erosive Oral Lichen Planus
Peptidyl-prolyl cis-trans isomerase FKBP1A
$LIPO
LIPELLA PHARMACEUTICALS INC.
0
catalysts
Phase 1
LP-410
tacrolimus
Graft Versus Host Disease (GVHD)
$LIPO
LIPELLA PHARMACEUTICALS INC.
0
catalysts
Phase 1
LPAR1 Antagonists
Fibrosis
Viva Star Biosciences (Suzhou) Co Ltd
0
catalysts
Phase 2
LPCN-1111
Male Hypogonadism
Verity Pharmaceuticals Inc
0
catalysts
Marketed
LPCN-1144
Jatenzo (testosterone undecanoate)
Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)
Androgen receptor
$LPCN
Lipocine Inc.
0
catalysts
Phase 1
LPXTI-641
Psoriatic Arthritis
Lapix Therapeutics Inc
0
catalysts
Phase 1
LR-19018
Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)
LG Chem Ltd
0
catalysts
Phase 1
LR-19123
Type 2 Diabetes
LG Chem Ltd
0
catalysts
Phase 1
LR-19155
Head And Neck Squamous Cell Carcinoma (HNSC)
LG Chem Ltd
0
catalysts
Preclinical
LRP-661
Epilepsy
London Research & Pharmaceuticals Ltd
0
catalysts
Phase 1
LS-01
Esophageal Squamous Cell Carcinoma (ESCC)
Guangzhou Liushun Biotechnology Co Ltd
0
catalysts
Preclinical
LSC Exosome Eye Injection
Age Related Macular Degeneration
$YDES
YD Bio Ltd
0
catalysts
Phase 1
LSLBP-002
Renal Cell Carcinoma
Shanghai Lishan Biopharmaceuticals Co Ltd
0
catalysts
Phase 2
LTI-03
Idiopathic Pulmonary Fibrosis
$RNTX
Rein Therapeutics, Inc.
0
catalysts
Preclinical
LTI-214
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Leukogene Therapeutics Inc
0
catalysts
Preclinical
LTX-568
Abdominal Pain
Lyntonix Inc
0
catalysts
Phase 1
LTZ-301
Diffuse Large B-Cell Lymphoma
LTZ Therapeutics Inc
0
catalysts
LUMISIGHT
LUMISIGHT (PEGULICIANINE)
LUMICELL
0
catalysts
LUNSUMIO
LUNSUMIO (MOSUNETUZUMAB-AXGB)
Genentech Inc
0
catalysts
LUPKYNIS
LUPKYNIS (VOCLOSPORIN)
1 INDICATIONS AND USAGE LUPKYNIS is indicated in combination with a backgroun…
Protein phosphatase 3 catalytic subunit alpha
$AUPH
Aurinia Pharmaceuticals Inc.
0
catalysts
Phase 2
LUT-014
Acne And Related Disorders
Lutris Pharma
0
catalysts
Preclinical
LUT-017
Wounds
Lutris Pharma
0
catalysts
Phase 2
LX-1001
Alzheimer's Disease
$LXEO
Lexeo Therapeutics, Inc.
0
catalysts
Phase 2
LX-2006
Cardiomyopathy
$LXEO
Lexeo Therapeutics, Inc.
0
catalysts
Phase 2
LX-2020
Cardiomyopathy
$LXEO
Lexeo Therapeutics, Inc.
0
catalysts
Phase 2
LXE-408
Leishmaniasis
$NVS
NOVARTIS AG
0
catalysts
